Previous 10 | Next 10 |
2023-06-26 14:29:18 ET Orchard Therapeutics ( NASDAQ: ORTX ) said that it has closed on a second $34M financing as part of a larger agreement that could garner the company up to $188M if certain regulatory milestones are met. The second financing included the issuance of 4.25M A...
Funding from second closing extends cash runway to mid-2025 to advance the company’s HSC gene therapy portfolio through several potential value-creating milestones OTL-200 (MLD) BLA submission initiated and on track for completion in mid-2023 with potential for U.S. approval in t...
BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at Stifel’s Inaugural Genetic Medicines Day on Tuesday, May 30, 2023 at 5:00 p.m. EDT. A webcast of...
2023-05-19 09:54:47 ET British biotech Orchard Therapeutics ( NASDAQ: ORTX ) on Friday announced new clinical data for its hematopoietic stem cell (HSC) gene therapy candidates in metabolic disorders Mucopolysaccharidosis type I (MPS-I) and Mucopolysaccharidosis type IIIA (MPS-IIIA)...
New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of motor skills Updated OTL-201 data from ongoing proof-of-concept study i...
Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of CAR-Treg cells from genetically engineered HSCs as a potential one-time treatmen...
2023-05-15 10:03:03 ET Orchard Therapeutics press release ( NASDAQ: ORTX ): Q1 GAAP EPS of -$0.12. Revenue of $1.23M (-77.7% Y/Y). For further details see: Orchard Therapeutics GAAP EPS of -$0.12, revenue of $1.23M
OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023 Libmeldy revenue and commercial patients treated expected to grow year-over-year in 2023 New clinical data in MPS-I and MPS-IIIA and pre-clinical data in genetic subsets of frontotemporal d...
Six presentations showcase the differentiated profile and broad applicability of the company’s HSC gene therapy platform Oral presentations in MPS-IH and MPS-IIIA and the progranulin form of frontotemporal dementia highlight leadership in neurometabolic and CNS diseases P...
2023-04-24 17:38:49 ET Summary Shares have lost a third of their value over the past year. HSC-based gene therapy Libmeldy is approved in the EU for MLD with a ~$3.5M price tag. Incidence could be higher than initial estimates. Cash position was bolstered with March financing,...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....